Clinical trial
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
NCT05395689 · Probelte Pharma S.L.U., Industry · Recruiting
Key facts
| NCT number | NCT05395689 |
|---|---|
| Title | Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM |
| Official title | Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis |
| Acronym | PROACAROS |
| Lead sponsor | Probelte Pharma S.L.U., Industry |
| Status | Recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | House Dust Mite Allergy |
| Intervention type | Biological |
| Interventions | House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo |
| Enrollment | 350 |
| Start date | Jan 17, 2022 |
| Primary completion | Jun 1, 2026 |
| Completion | Jun 1, 2026 |
| First posted | May 27, 2022 |
| Last update posted | Jul 18, 2024 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: